The experimental treatment AP-101 may help ALS patients preserve body weight, trial data show. Preservation of body weight is ...

A longitudinal study of 100 ALS patients shows that combined serum levels of 4-HNE, LBP, and NfL discriminate rapid disease progression and poor survival with high accuracy.

ALS (amyotrophic lateral sclerosis) is a fatal neurodegenerative disease that gradually affects a person's ability to move, speak and breathe. It advances differently in every patient. Now, ...

A new drug may slow progression of -- and even reverse -- symptoms of a rare form of amyotrophic lateral sclerosis, or ALS, a new study published Monday finds. The drug, tofersen, targets a very ...

ⓘ This article is third-party content and does not represent the views of this site. We make no guarantees regarding its accuracy or completeness. First clinical development program in sporadic ALS ...

ZURICH--AL-S Pharma AG ("AL-S Pharma" or "the Company"), a clinical-stage biotechnology company discovering and developing human antibodies that target misfolded proteins implicated in amyotrophic ...

There could be new hope for ALS management as a promising drug enters phase 3 clinical trials. ALS is a progressive disease in which the brain loses connection with the muscles, The ALS Association ...

Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease in which motor neurons are gradually lost, leading to muscle weakness and, as the disease advances, difficulty breathing ...

Shanghai Zhimeng Biopharma, Inc. ( "Zhimeng Biopharma") announced today that its independently developed next-generation ...

Forbes contributors publish independent expert analyses and insights. Physician who writes about the rising rates of cancer in young adults. This voice experience is generated by AI. Learn more. This ...

Congress passed the ACT for ALS extending research funding beyond the end of the decade, but patients are still battling for ...